Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-11-30

Study Completion Date

2011-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present study will assess the low-density lipoprotein cholesterol (LDL-C) lowering effect of colesevelam as an adjunct to niacin for the improvement of lipids and glycemic control in dyslipidemic subjects with impaired fasting glucose.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL

NCT00079638

Dyslipidemia Coronary Heart Disease Atherosclerosis +2 more

COMPLETED PHASE4

A Study of the Safety and Efficacy of Patients With Familial Hypercholesterolaemia Taking Colesevelam as add-on Therapy to Their Existing Medication

NCT00655265

Familial Hypercholesterolemia

COMPLETED PHASE4

Cholesterol-Lowering Atherosclerosis Study (CLAS)

NCT00000599

Arterial Occlusive Diseases Cardiovascular Diseases Carotid Artery Diseases +7 more

COMPLETED PHASE3

Colesevelam, Lipids And Sugars, South Asian Canadian Trial

NCT02504736

Dyslipidemia

COMPLETED

Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis

NCT01250990

Dyslipidemias

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyslipidemia Hyperlipidemia Hyperglycemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

6 tablets daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks

Colesevelam

Group Type EXPERIMENTAL

Colesevelam

Intervention Type DRUG

6 tablets (3750 mg total) daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

6 tablets daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks

Intervention Type DRUG

Colesevelam

6 tablets (3750 mg total) daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Welchol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men and women ≥ 18 years of age.
2. Non-HDL-C ≥100 mg/dL and ≤220 mg/dL at Visits 1 and 2.
3. FPG ≥90 mg/dL and ≤145 mg/dL, at Visits 1 and 2.
4. HDL-C \<60 mg/dL at Visits 1 and 2, regardless of gender.
5. Untreated dyslipidemia, or statin treatment only with equipotency to atorvastatin ≤40 mg daily for at least 12 weeks prior to Screening Visit 1 and without change or initiation prior to randomization

Exclusion Criteria

1. Known intolerance to niacin or bile acid-sequestering drugs or aspirin.
2. Any contraindication to a study medication (niacin, aspirin or colesevelam).
3. History of dysphagia, swallowing disorders or intestinal motility disorders.
4. History of pancreatitis.
5. Fasting TG \>500 mg/dL at Visits 1 and 2
6. Currently taking medication for diabetes mellitus, Type 1 or 2,or currently taking glucose-lowering drugs (e.g. metformin) for any other indication.
7. Currently taking drugs that may affect glycemic and/or lipid control (e.g., beta-blockers, etc.) if started within the 12 weeks prior to Visit 1, or prior to randomization. This does not apply to dietary supplements.).
8. Body mass index (BMI) \>40 kg/m2.
9. History of acute myocardial infarction, unstable angina, transient ischemic attacks, stroke or revascularization procedure within the 3 months prior to Visit 1 or prior to randomization.
10. Use of prescription strength niacin, bile acid sequestrants, fibrates or omega-3 fatty acids within 8 weeks prior to Visit 1 or prior to randomization. This does not apply to dietary supplements.
11. Unwilling to abstain, during the study, from weight-loss drugs (including over-the-counter) or weight-loss programs during the study.
12. Current use, or intended use during the study, of cyclic hormones (e.g., oral or vaginal contraceptives and estrogen replacement therapy).
13. Females who are pregnant, planning to be pregnant during the study period, lactating, or women of childbearing potential not using an acceptable method of contraception. Acceptable methods include intrauterine device, cervical diaphragm plus spermicide, female condom plus spermicide, or partner's use of condoms plus spermicide. Partner's vasectomy only or use of condoms or spermicide only are not considered acceptable forms of birth control.
14. Current use, or intended use during the study of cyclosporine.
15. Recent history (past 12 months) of illicit drug use or excessive ethanol use. Excessive ethanol use will be defined as \>14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz hard liquor).
16. Exposure to any investigational agent within 30 days prior to Visit 1, and prior to randomization.
17. Individual has a condition the Investigator believes would interfere with his ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No